Serum Levels of MiR-146a in Patients with Psoriasis
Overview
Pathology
Pharmacology
Authors
Affiliations
Background: Psoriasis is an immune-mediated disease with interactions between genetic and environmental factors. An increasing number of studies are demonstrating the importance of microRNAs (miRNAs) in the pathogenesis of psoriasis. miR-146a, a dominant negative regulator of inflammation, has been consistently reported as overexpressed in the skin and peripheral blood mononuclear cells (PBMCs) of patients with psoriasis. Expression and/or function of this miRNA is highly influenced by genetic variations, some of which have already been associated with susceptibility to psoriasis.
Objective: We sought to study the importance of miR-146a in patients with moderate-to-severe psoriasis and to understand the impact of rs57095329 and rs2910164 polymorphisms in a psoriatic Portuguese population.
Methods: miR-146a circulating levels were quantified using molecular biology techniques in 99 patients with moderate-to-severe psoriasis (35 female, 64 male; age 47.4 ± 10.9 years) and 78 healthy individuals (52 female, 26 male; age 42.4 ± 10.1 years). miRNA expression was correlated with clinicopathological features as well as with genetic data such as the presence of human leukocyte antigen (HLA)-C*0602 allele and two miR-146a polymorphisms (rs2910164 and rs57095329).
Results: miR-146a serum levels were 3.7-fold higher in patients with psoriasis than in controls (p < 0.0001, area under the curve [AUC] 0.75; 95% confidence interval [CI] 0.66-0.83). Of note, miR-146a circulating levels positively correlated with Psoriasis Area and Severity Index (p < 0.05) and body surface area (p < 0.05) indexes. No variations in miR-146a levels were observed with rs2910164 and rs57095329 genotypes.
Conclusion: Circulating miR-146a levels were upregulated in patients with psoriasis, especially in those with active disease. To the best of our knowledge, this is the largest study with a homogenous psoriasis population, and our data could shed light on the pathogenesis of psoriasis, paving the way for new avenues for disease treatment.
Psoriasis Treatments: Emerging Roles and Future Prospects of MicroRNAs.
Teo L, Juantuah-Kusi N, Subramanian G, Sampath P Noncoding RNA. 2025; 11(1).
PMID: 39997616 PMC: 11858470. DOI: 10.3390/ncrna11010016.
Letonja J, Petrovic D Biomedicines. 2024; 12(6).
PMID: 38927529 PMC: 11201627. DOI: 10.3390/biomedicines12061322.
MicroRNA-146a Signature in Psoriasis: A Systematic Review and Meta-Analysis.
Ho P, Huang Y Mol Diagn Ther. 2024; 28(4):379-388.
PMID: 38773009 DOI: 10.1007/s40291-024-00714-0.
Selected miRNA and Psoriasis-Cardiovascular Disease (CVD)-Overweight/Obesity Network-A Pilot Study.
Michalak-Stoma A, Walczak K, Adamczyk M, Kowal M, Krasowska D Int J Mol Sci. 2023; 24(18).
PMID: 37762217 PMC: 10530775. DOI: 10.3390/ijms241813916.
The Essential Role of microRNAs in Inflammatory and Autoimmune Skin Diseases-A Review.
Dopytalska K, Czaplicka A, Szymanska E, Walecka I Int J Mol Sci. 2023; 24(11).
PMID: 37298095 PMC: 10253000. DOI: 10.3390/ijms24119130.